Moderna, Inc. Stock price

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 15:33:02 2024-02-23 EST 5-day change 1st Jan Change
95.38 USD -4.08% Intraday chart for Moderna, Inc. +8.36% -3.71%
Sales 2023 6.85B 9.24B Sales 2024 * 4.27B 5.76B Capitalization 37.91B 51.17B
Net income 2023 -4.71B -6.36B Net income 2024 * -2.77B -3.74B EV / Sales 2023 5.54 x
Net cash position 2023 * 5.57B 7.51B Net cash position 2024 * 3.59B 4.84B EV / Sales 2024 * 8.04 x
P/E ratio 2023
-8.07 x
P/E ratio 2024 *
-13.9 x
Employees 3,900
Yield 2023 *
-
Yield 2024 *
-
Free-Float 90.37%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.67%
1 week+8.76%
Current month-4.89%
1 month-5.70%
3 months+22.40%
6 months-16.76%
Current year-3.36%
More quotes
1 week
85.53
Extreme 85.53
101.73
1 month
84.06
Extreme 84.06
105.81
Current year
84.06
Extreme 84.06
115.97
1 year
62.55
Extreme 62.55
163.24
3 years
62.55
Extreme 62.55
497.49
5 years
11.54
Extreme 11.54
497.49
10 years
11.54
Extreme 11.54
497.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 11-02-28
President 48 12-12-31
Director of Finance/CFO 47 22-09-05
Members of the board TitleAgeSince
Director/Board Member 65 18-05-31
Director/Board Member 74 20-06-30
Director/Board Member 67 19-12-10
More insiders
Date Price Change Volume
24-02-23 95.82 -3.65% 3 326 934
24-02-22 99.44 +13.53% 11,354,471
24-02-21 87.59 +0.69% 3,759,970
24-02-20 86.99 -1.56% 3,140,293
24-02-16 88.37 -3.04% 3,708,097

Delayed Quote Nasdaq, February 23, 2024 at 01:48 pm

More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
99.44 USD
Average target price
133.3 USD
Spread / Average Target
+34.04%
Consensus
  1. Stock
  2. Equities
  3. Stock Moderna, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer